These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33301829)

  • 1. Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence.
    Volpe M; Bauersachs J; Bayés-Genís A; Butler J; Cohen-Solal A; Gallo G; Deichl AS; Khan MS; Battistoni A; Pieske B; Saito Y; Zieroth S
    Int J Cardiol; 2021 Mar; 327():138-145. PubMed ID: 33301829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes.
    Ji Q
    Clin Cardiol; 2024 Feb; 47(2):e24192. PubMed ID: 38013641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.
    Silva-Cardoso J; Fonseca C; Franco F; Morais J; Ferreira J; Brito D
    Rev Port Cardiol (Engl Ed); 2021 Dec; 40(12):975-983. PubMed ID: 34922707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan.
    Volpe M; Gallo G; Zieroth S
    Cardiology; 2022; 147(1):23-25. PubMed ID: 34587618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis.
    Kerwagen F; Riemer U; Wachter R; von Haehling S; Abdin A; Böhm M; Schulz M; Störk S
    Lancet Reg Health Eur; 2023 Dec; 35():100778. PubMed ID: 38023333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
    Docherty KF; Campbell RT; Brooksbank KJM; Godeseth RL; Forsyth P; McConnachie A; Roditi G; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    ESC Heart Fail; 2021 Feb; 8(1):129-138. PubMed ID: 33305513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe.
    Lin DS; Wang TD; Buranakitjaroen P; Chen CH; Cheng HM; Chia YC; Sukonthasarn A; Tay JC; Teo BW; Turana Y; Wang JG; Kario K;
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):556-567. PubMed ID: 33305531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Piepoli MF; Hussain RI; Comin-Colet J; Dosantos R; Ferber P; Jaarsma T; Edelmann F
    Eur J Heart Fail; 2021 Jan; 23(1):127-135. PubMed ID: 33314487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!
    Dschietzig TB; Rosano GMC; Anker SD
    ESC Heart Fail; 2020 Dec; 7(6):3274-3277. PubMed ID: 33320445
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19.
    Rubattu S; Gallo G; Volpe M
    Front Cardiovasc Med; 2020; 7():616564. PubMed ID: 33330677
    [No Abstract]   [Full Text] [Related]  

  • 12. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
    Dickert NW; Mitchell AR; Venechuk GE; Matlock DD; Moore MA; Morris AA; Pierce KJ; Speight CD; Allen LA
    Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007070. PubMed ID: 33302715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.
    Okada K; Hoshide S; Kato M; Kanegae H; Ishibashi S; Kario K
    J Clin Hypertens (Greenwich); 2021 Apr; 23(4):860-869. PubMed ID: 33326172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo?
    Riello RJ; Pitt B
    JACC Heart Fail; 2021 Jan; 9(1):25-27. PubMed ID: 33309576
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficial effects of one-month sacubitril/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy.
    Papa AA; Gallinoro E; Palladino A; Golino P
    Acta Myol; 2020 Sep; 39(3):136-140. PubMed ID: 33305170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure.
    Correale M; Tricarico L; Ferraretti A; Formica ES; Padovano G; Monaco I; Merolla G; Tozzi V; Di Biase M; Iacoviello M; Brunetti ND
    J Cardiovasc Med (Hagerstown); 2021 Jun; 22(6):508-510. PubMed ID: 33315691
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
    Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARNI and SGLT2i: a promising association to be used with caution.
    Herbst A; Orso F; Migliorini M; Virciglio S; Tognelli S; Camartini V; Pratesi A; Fattirolli F; Marchionni N; Ungar A; Baldasseroni S
    J Geriatr Cardiol; 2020 Nov; 17(11):728-732. PubMed ID: 33343652
    [No Abstract]   [Full Text] [Related]  

  • 19. Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients.
    Ibrahim NE; Januzzi JL
    Clin Chem; 2021 Jan; 67(1):79-86. PubMed ID: 33316036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin Receptor and Neprylisin Inhibitor: A new drug in pediatric cardiologist's armamentarium.
    Arya A; Azad S; Sitaraman R
    Ann Pediatr Cardiol; 2020; 13(4):334-336. PubMed ID: 33311922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.